DNB Asset Management AS Has $19.57 Million Holdings in Axon Enterprise, Inc $AXON

DNB Asset Management AS increased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 24.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,267 shares of the biotechnology company’s stock after purchasing an additional 5,379 shares during the period. DNB Asset Management AS’s holdings in Axon Enterprise were worth $19,568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stone House Investment Management LLC acquired a new position in shares of Axon Enterprise in the 3rd quarter valued at $29,000. New Millennium Group LLC bought a new stake in Axon Enterprise in the third quarter valued at about $29,000. Root Financial Partners LLC acquired a new position in Axon Enterprise in the third quarter worth about $34,000. Darwin Wealth Management LLC acquired a new position in Axon Enterprise in the second quarter worth about $37,000. Finally, NewSquare Capital LLC lifted its stake in Axon Enterprise by 96.2% during the second quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 25 shares during the period. 79.08% of the stock is owned by institutional investors.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Insiders Place Their Bets

In other Axon Enterprise news, CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the transaction, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. The trade was a 1.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 1,134 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the transaction, the chief accounting officer owned 13,740 shares in the company, valued at $8,244,000. The trade was a 7.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 58,040 shares of company stock valued at $32,251,738 over the last three months. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Down 1.4%

NASDAQ AXON opened at $542.40 on Friday. The stock’s 50 day simple moving average is $537.92 and its 200 day simple moving average is $625.54. Axon Enterprise, Inc has a one year low of $396.41 and a one year high of $885.91. The firm has a market cap of $43.61 billion, a PE ratio of 356.84, a price-to-earnings-growth ratio of 16.57 and a beta of 1.48. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.08 EPS. As a group, sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Barclays lowered their price objective on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Needham & Company LLC lowered their price target on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. UBS Group cut their price objective on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research note on Wednesday. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.